Dendritic Cell Specific Neutra™ Antibody Products

Are you struggling with inefficient immune response modulation or unpredictable outcomes in dendritic cell (DC)-based therapies? Creative Biolabs' dendritic cell specific Neutra™ antibody products leverage advanced monoclonal antibody engineering and high-throughput functional validation to overcome these challenges, accelerating therapeutic development with precision tools for DC-targeted immune modulation.

Introduction to Dendritic Cells

Dendritic cells (DCs), first identified by Steinman in 1973, are the most potent antigen-presenting cells (APCs) in the immune system. Derived from hematopoietic stem cells, DCs are categorized into myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). These cells bridge innate and adaptive immunity by capturing, processing, and presenting antigens to T cells, thereby initiating and regulating immune responses. Their unique ability to activate naïve T cells positions DCs as central orchestrators of immunity.

• Structure

DCs exhibit distinct structural features across maturation stages. Immature DCs possess membrane protrusions for antigen capture, while mature DCs upregulate surface MHC II complexes and co-stimulatory molecules (e.g., CD80, CD86) to optimize T cell activation. Recent cryo-EM studies reveal that spatial reorganization of cytoskeletal proteins during maturation enhances antigen presentation efficiency.

• Related Signaling Pathways

DCs integrate signals via pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), which detect pathogen-associated molecular patterns (PAMPs). TLR7/9 activation in pDCs triggers IFN-α/β production via MyD88-IRF7, crucial for antiviral responses. Additionally, NF-κB and MAPK pathways mediate inflammatory cytokine secretion, influencing T cell differentiation. DCs also modulate immune tolerance through PD-L1/CTLA-4 signaling, balancing immunity and immune evasion.

• Associated Pathologies

Dysregulated DC function underpins multiple diseases:

- Cancer: Tumor-infiltrating DCs often exhibit tolerogenic phenotypes, impairing antitumor immunity.

- Autoimmune Diseases: Overactive DCs promote aberrant T cell responses in conditions like rheumatoid arthritis and experimental autoimmune myasthenia gravis.

- Viral Infections: Impaired DC maturation compromises antiviral defense, as seen in chronic viral infections.

Fig.1 The role of DCs in the induction of immune tolerance and immune response.¹

Applications of Dendritic Cell-Neutralizing Antibodies

• Enhancing Cancer Immunotherapies

Anti-DC antibodies improve checkpoint inhibitor efficacy by reprogramming tumor-associated DCs from immunosuppressive to immunostimulatory states. For instance, blocking IL-10 signaling in DCs enhances T cell infiltration in melanoma models.

• Mitigating Autoimmunity

In experimental autoimmune myasthenia gravis, anti-DC monoclonal antibodies reduce disease severity by disrupting pathogenic T cell priming. Similarly, antibodies targeting DC-derived cytokines (e.g., TNF-α) alleviate symptoms in rheumatoid arthritis.

• Antiviral and Vaccine Development

pDC-targeted antibodies neutralizing IFN-α limit immunopathology in severe viral infections while preserving antiviral immunity. Conversely, agonist antibodies activating DCs via CD40 enhance vaccine-induced T cell responses.

Anti-Dendritic Cells Antibodies

Creative Biolabs' anti-DC antibodies enable precise manipulation of DC biology for research:

- Surface Marker-Specific Antibodies: Anti-CD11c, anti-CD83, and anti-CD209 antibodies isolate or deplete DC subsets, facilitating functional studies.

- Functional Neutralizing Antibodies: Antibodies blocking IL-12, IFN-α, or PD-L1 modulate DC-driven immune activation or tolerance. For example, anti-DC monoclonal antibodies significantly suppress autoimmune responses in preclinical models by inhibiting antigen presentation.

- Therapeutic Antibodies: Antibodies targeting DC-specific receptors (e.g., CLEC9A) enhance cancer vaccine efficacy by promoting cross-presentation of tumor antigens.

Creative Biolabs provides dendritic cell specific Neutra™ antibody products that are engineered to address the complexities of DC-mediated immunity, offering unmatched specificity for research and therapeutic development. Our portfolio includes antibodies validated in flow cytometry, ELISA, and in vivo models. Contact our team today to explore how these tools can advance your projects.

REFERENCE

1. Cheng, Hao, et al. "Signaling pathways involved in the biological functions of dendritic cells and their implications for disease treatment." Molecular Biomedicine 4.1 (2023): 15. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s43556-023-00125-3